^
Association details:
Biomarker:PAK4 deletion
Cancer:Solid Tumor
Drug Class:PD1 inhibitor
Direction:Resistant
Evidence:
Evidence Level:
Resistant: D – Preclinical
New
Source:
Title:

PAK4 inhibition improves PD-1 blockade immunotherapy

Excerpt:
It has been postulated that cancer cell-intrinsic mechanisms may actively exclude T cells from tumors...In mouse models, genetic deletion of PAK4 increased T cell infiltration and reversed resistance to PD-1 blockade in a CD8 T cell-dependent manner.
DOI:
10.1038/s43018-019-0003-0